Vincristine sulfate as single-agent chemotherapy in a dog and a cat with malignant neoplasms.
A 12-year-old 4-kg spayed domestic shorthair cat with a poorly differentiated fibrosarcoma of the rostral aspect of the mandible and an 11-year-old 13-kg castrated dog of mixed breeding with pulmonary metastatic hemangiosarcoma were treated with 0.5 mg of vincristine sulfate/m2 of body surface, IV, weekly. Three months after beginning treatment, both animals had complete clinical remission. The role of this vinca alkaloid as a single agent for malignant neoplasms has seldom been discussed in the veterinary scientific literature. The results of these two cases indicate that single-agent vincristine sulfate chemotherapy is effective in the treatment of feline fibrosarcoma and canine hemangiosarcoma.
Hahn
K A
KA
Department of Veterinary Clinical Sciences, School of Veterinary Medicine, Purdue University, West Lafayette, IN 47907.
D000818:Animals; D002371:Cat Diseases / Q000188:drug therapy*; D002415:Cats; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D005260:Female; D005354:Fibrosarcoma / Q000188:drug therapy / Q000662:veterinary*; D006394:Hemangiosarcoma / Q000188:drug therapy / Q000556:secondary / Q000662:veterinary*; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary / Q000662:veterinary; D008297:Male; D008339:Mandibular Neoplasms / Q000188:drug therapy / Q000662:veterinary; D013160:Splenic Neoplasms / Q000662:veterinary; D014750:Vincristine / Q000627:therapeutic use*
D014750:Vincristine